Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2017 | What is the future of treating ALL?

Susan O’Brien • 1 Jun 2017
ASCO 2017
Acute Lymphoblastic Leukemia Inotuzumab ozogamicin Ponatinib

Susan O’Brien, MD from the University of California, Irvine, CA discusses the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) at the American Society of Oncology (ASCO) 2017 Annual Meeting held in Chicago, IL. Referencing two studies evaluating the effectiveness of ponatinib or inotuzumab ozogamicin with low-dose chemotherapy in treating ALL (NCT00671658) (NCT01230788), she notes that both trials had promising results and the future for ALL treatment appears to be positive.

More from Susan O’Brien

Venetoclax and obinutuzumab combination therapy for CLL
2:03
Venetoclax and obinutuzumab combination therapy for CLL
Susan O’Brien • 14 Jun 2019
CAR T-cell therapy updates in CLL
2:19
CAR T-cell therapy updates in CLL
Susan O’Brien • 14 Jun 2019
CLL RESONATE-2: Five-year follow-up
2:00
CLL RESONATE-2: Five-year follow-up
Susan O’Brien • 13 Jun 2019
Zanubrutinib and acalabrutinib for CLL: potential alternatives to ibrutinib?
3:19
Zanubrutinib and acalabrutinib for CLL: potential alternatives to ibrutinib?
Susan O’Brien • 15 Jun 2019

Related Videos

Advances in precision-engineered T-cell immunotherapy for alloSCT in AML, ALL and MDS
10:54
Advances in precision-engineered T-cell immunotherapy for alloSCT in AML, ALL and MDS
Samer Srour • 19 Sep 2026
New horizons in Ph+ ALL: the evolving role of bispecific antibodies
1:20
New horizons in Ph+ ALL: the evolving role of bispecific antibodies
Josep-Maria Ribera • 14 Sep 2026
NGS-MRD assessment and targeted treatment selection in ALL
1:48
NGS-MRD assessment and targeted treatment selection in ALL
Josep-Maria Ribera • 14 Sep 2026
Avoiding common pitfalls when managing patients with ALL outside of specialist centers
3:52
Avoiding common pitfalls when managing patients with ALL outside of specialist centers
Bijal Shah • 10 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals